TL;DR
The results may establish evidence supporting the omission of adjuvant chemotherapy in premenopausal women with low genomic risk scores and limited nodal involvement, potentially reducing treatment-related morbidity while preserving comparable oncologic outcomes.
AI-generated by Semantic Scholar